Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shWTAP is an experimental short hairpin RNA (shRNA) designed to silence the expression of Wilms' tumor 1-associating protein (WTAP). WTAP is a key component of the m6A methyltransferase complex and is frequently upregulated in various cancers, including glioblastoma multiforme (GBM). By knocking down WTAP, shWTAP inhibits cancer cell proliferation and reduces stem-cell-like properties (stemness) in patient-derived cancer stem cells. Research indicates that WTAP plays a role in post-transcriptional regulation by decreasing intron retention and increasing exon skipping. shWTAP serves as a research tool to investigate the oncogenic role of WTAP and its potential as a therapeutic target in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shWTAP.